Baudax Bio (BXRX) Misses Q2 EPS by $1.07

Baudax Bio (NASDAQ: BXRX) reported Q2 EPS of ($1.72), $1.07 worse than the analyst estimate of ($0.65).

“The second quarter of 2020 was most important because of the full commercial launch of ANJESO,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio. “We believe that with our experienced acute care sales force, receipt of our J-code from the Centers for Medicare and Medicaid Services (CMS) (effective in October 2020), entry into an agreement with the Group Purchasing Organization (GPO) Vizient Inc., and other strategic initiatives underway, we are well positioned to continue to target the acute care space. We look forward to continuing to raise awareness and educate acute care providers about ANJESO as an advantageous option for the management of moderate to severe pain.”

For earnings history and earnings-related data on Baudax Bio (BXRX) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22
• INVO Fertility (IVF) Tops Q2 EPS by 105c